Hengrui PD-1 monoclonal antibody has once again submitted an application for listing in the USA. Will it replicate the approval path of Keytruda monoclonal antibody? | Speed Reading Announcement
①Today, jiangsu hengrui pharmaceuticals announced that it will resubmit the application for approval of Carirelizumab in the USA, after previously receiving a Complete Response Letter (CRL) from the US FDA, causing a delay; ②Junshi Bio's PD-1 variety also experienced delays in the USA but eventually succeeded in getting approved, industry insiders suggest that hengrui may replicate this process; ③If successfully approved in the USA, it would be of great significance to hengrui pharmaceuticals' global strategy.
Star Evening News | Minmetals New Energy, bio-thera solutions, and 6 other companies have announced their shareholding reduction plans. Zhongheng shares receive the Sichuan Securities Regulatory Bureau's administrative supervision decision.
1. Guangdong may introduce demonstration clauses for multiple technology insurances such as biomedical and integrated circuits; 2. Shenzhen: Accelerating the establishment of a billion-dollar Shenzhen semiconductor and integrated circuit industry investment fund; 3. Shanghai Stock Exchange terminates the review of Feixiang Technology's star board issuance and listing.
Intensifying competition in the domestic CRO market is eroding profits, BiDe Pharmaceutical claims it will strengthen its overseas market | Direct hit earnings conference
①Affected by factors such as the slowdown in funding for innovative drugs and the increased competition among CRO companies, the domestic revenue of BiDe Medical continues to decline, dragging down overall performance and leading to a sharp decline in net income; ②In contrast, overseas market revenue is still growing. Chairman of BiDe Medical, Dai Lan, revealed that in the future, they will correspondingly increase overseas BD personnel to carry out promotional work.
Bullish on A-shares? Foreign capital bypasses Hong Kong stock ETFs, with institutions suggesting that incremental capital for Chinese stocks may reach 40 billion US dollars.
Institutions predict that Chinese stock potential incremental funds may reach 40 billion US dollars. Which directions will be the focus of increasing positions?
What happened during the National Day holiday at home and abroad? Here is a summary of important financial news.
①The Shanghai Stock Exchange: Will extend the acceptance of designated trading order instructions starting from October 8; Goldman Sachs has raised the Chinese stock market to "overweight", expecting a further increase of 15-20%; ②The Hong Kong stock market is booming, with a high growth in the number of brokerage account openings and margin trading data in Hong Kong in the past week; Many places have introduced optimization policies for real estate, and the market has responded positively.
Hong Kong stocks become the "hottest" stock market in the world! The Hang Seng Index has risen nearly 40% so far this year, with brokerage stocks surging sixfold in five days. How will the future market evolve?
It is noteworthy that brokerage stocks, as the vanguards of the bull market, play the role of "front-runners" in this current uptrend. Moreover, Chinese-affiliated brokerage stocks in the Hong Kong market have shown astonishing increases, indicated by the gains over the past five trading days.